Search

Your search keyword '"Calfa, Carmen Julia"' showing total 14 results
Start Over Author "Calfa, Carmen Julia"
14 results on '"Calfa, Carmen Julia"'

2. Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Author

Calfa, Carmen Julia, primary, Nangia, Chaitali Singh, additional, Barve, Minal A., additional, Rowland, Kendrith M., additional, Boccia, Ralph V., additional, Knecht, John George, additional, Chang, Mingjin, additional, Salgado, Marcela, additional, Bayer, Blaise, additional, Aghajanian, Tamar, additional, Williams, William, additional, Wiseman, Charles L., additional, Del Priore, Giuseppe, additional, and Chumsri, Saranya, additional

Published
2024
Full Text
View/download PDF

3. Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Srkalovic, Gordan, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Nazemzadeh, Reza, additional, Cannon, Timothy Lewis, additional, Duvivier, Herbert Leon, additional, Yost, Kathleen J, additional, Pakkala, Suchita, additional, Alva, Ajjai Shivaram, additional, Behl, Deepti, additional, Gold, Philip Jordan, additional, Calfa, Carmen Julia, additional, Ngirailemesang, Melissa, additional, Powell, Steven Francis, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

4. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.

Author

Meric-Bernstam, Funda, primary, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Gutierrez, Rodolfo, additional, Ahn, Eugene R, additional, Cannon, Timothy Lewis, additional, Powell, Steven Francis, additional, Krauss, John C., additional, Reynolds, Christopher M., additional, von Mehren, Margaret, additional, Behl, Deepti, additional, Calfa, Carmen Julia, additional, Duvivier, Herbert Leon, additional, Kaplan, Henry G., additional, Livingston, Michael B., additional, Sharma, Manish, additional, Urba, Walter John, additional, O'Lone, Raegan, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

6. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Ahn, Eugene R, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Calfa, Carmen Julia, additional, Alva, Ajjai Shivaram, additional, Suhag, Vijay S., additional, Hamid, Omid, additional, Dotan, Efrat, additional, Yang, Eddy Shih-Hsin, additional, Alese, Olatunji B., additional, Yost, Kathleen J, additional, Marr, Alissa S., additional, Palmer, Martin Clive, additional, Thompson, Forrest L., additional, Rygiel, Andrew Lawrence, additional, Anderson, Sarah T., additional, Islam, Samiha, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

7. Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition.

Author

Williams, William, primary, Dakhil, Shaker R., additional, Calfa, Carmen Julia, additional, Holmes, Jarrod P., additional, Bhattacharya, Saveri, additional, Lukas, Jason Jerome, additional, Tan-Chiu, Elizabeth, additional, Peoples, George Earl, additional, Sunkari, Vivekananda, additional, Lacher, Markus, additional, and Wiseman, Charles L., additional

Published
2020
Full Text
View/download PDF

8. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Alva, Ajjai Shivaram, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Khalil, Maged F., additional, Ahn, Eugene R, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Fisher, Julie Gottlieb, additional, Haslem, Derrick S., additional, Shrestha, Sagun, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Warren, Sasha L., additional, Rygiel, Andrew Lawrence, additional, Ranasinghe, Shamika, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

9. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Ahn, Eugene R, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Dib, Elie G., additional, Haggstrom, Daniel Ernest, additional, Alguire, Kathryn B., additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Gaba, Anu G., additional, Marr, Alissa S., additional, Sangal, Ashish, additional, Thota, Ramya, additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Rygiel, Andrew Lawrence, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

10. Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Calfa, Carmen Julia, Rothe, Michael, Srkalovic, Gordan, Duvivier, Herbert Leon, Behl, Deepti, Straughn, J Michael, Yost, Kathleen J, Mehmi, Inderjit, Pisick, Evan P., Sharma, Bhavina B, Thota, Ramya, Veljovich, Dan Steven, Alese, Olatunji B., Cannon, Timothy Lewis, Gaba, Anu G., Urba, Walter John, von Mehren, Margaret, Grantham, Gina N., Halabi, Susan, and Schilsky, Richard L.

Published
2023
Full Text
View/download PDF

11. Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC).

Author

LeCroy, Nicholas Martin, primary, Borrero, Irene, additional, Dumercy, Dina Bernie, additional, Velis, Evelio, additional, Perez, Alejandra T., additional, Velez, Michel, additional, Mani, Aruna, additional, Castrellon, Aurelio Bartolome, additional, Hawkins Locke, Carla, additional, Frankel, Cynthia, additional, Sareli, Candice, additional, and Calfa, Carmen Julia, additional

Published
2015
Full Text
View/download PDF

12. Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer.

Author

Knutson, Keith L., primary, Clynes, Raphael A., additional, Yeramian, Patrick, additional, Kemp, Kathleen P., additional, Shreeder, Barath, additional, Ballman, Karla V., additional, Tenner, Kathleen S., additional, Erskine, Courtney L., additional, Norton, Nadine, additional, Northfelt, Donald W., additional, Tan, Winston, additional, Pegram, Mark D., additional, Calfa, Carmen Julia, additional, Mittendorf, Elizabeth Ann, additional, and Perez, Edith A., additional

Published
2015
Full Text
View/download PDF

13. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52.

Author

Clynes, Raphael, primary, Knutson, Keith L., additional, Ballman, Karla V., additional, Erskine, Courtney L., additional, Norton, Nadine, additional, Sumrall, Susan V., additional, Northfelt, Donald W., additional, Tan, Winston, additional, Calfa, Carmen Julia, additional, Pegram, Mark D., additional, and Perez, Edith A., additional

Published
2013
Full Text
View/download PDF

14. Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831.

Author

Knutson, Keith L., primary, Perez, Edith A., additional, Ballman, Karla V., additional, Erskine, Courtney L., additional, Fox, Nicholas, additional, McCarl, Christie-Ann, additional, Norton, Nadine, additional, Sumrall, Susan V., additional, Northfelt, Donald W., additional, Tan, Winston, additional, Calfa, Carmen Julia, additional, Pegram, Mark D., additional, and Clynes, Raphael, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results